ARRY - アレイ・バイオファ―マ （Array BioPharma Inc.） アレイ・バイオファ―マARRYのチャート
ARRYの企業情報
| symbol | ARRY |
|---|---|
| 会社名 | Array BioPharma Inc. （アレイ・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アレイ・バイオファーマ（Array BioPharma Inc.）は、癌に罹患した患者を治療するための標的化された小分子薬物の発見、開発、および商業化に焦点を当てた生物医薬品会社である。同社のプログラムには、約3種類のがん剤、ビニメチニブ、エンコラフェニブおよびセルメチニブ（AstraZeneca、PLCと提携）が含まれている。そのビニメチニブおよびエンコラフェニブは進行癌患者の第III相試験中であり、BRAF突然変異メラノーマ患者のビニメチニブと併用してエンコファニブを試験するCOLUMBUS試験を含み、BRAF V600E突然変異結腸直腸癌（BRAFm CRC）患者のビシメチニブおよびセツキシマブと組み合わせてエンコラフェニブを試験するBEACON CRC試験を開始した。そのセルメチニブは、癌のためのマイトジェン活性化プロテインキナーゼ（MEK）阻害剤であり、これは第III相試験中である。同社の先進的な臨床段階の薬剤には、Filanesib、ARRY-797、ASC08 / Danoprevir、Ipatasertib / GDC-0068、Motolimod / VTX-2337、LOXO-101、ONT-380 / ARRY-380、GDC-0575、GDC-0994およびARRY -382が含まれる。 アレイ・バイオファ―マは、米国のバイオ医薬品会社。主に癌患者の治療向け低分子薬の発見、開発、商業化に従事。全額出資の臨床段階の薬剤は、多発性骨髄腫のためのキネシンスピンドルタンパク質阻害剤ARRY-520、ラミンA / C関連の拡張型心筋症のためのp38阻害剤ARRY-79など。本社はコロラド州ボ―ルダ―。 Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. |
| 本社所在地 | 3200 Walnut Street Boulder CO 80301 USA |
| 代表者氏名 | Carrie S. Cox キャリーS.コックス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 303-381-6600 |
| 設立年月日 | 35827 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 298人 |
| url | www.arraybiopharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arry |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -127.69100 |
| 終値（lastsale） | 13.665 |
| 時価総額（marketcap） | 2909574880.185 |
| 時価総額 | 時価総額（百万ドル） 3291.769 |
| 売上高 | 売上高（百万ドル） 173.76800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2991.057 |
| 当期純利益 | 当期純利益（百万ドル） -147.34600 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Array Biopharma Inc revenues increased 15% to $173.8M. Net loss increased 26% to $147.3M. Revenues reflect Asia Pacific segment increase from $3.8M to $46.1M. Higher net loss reflects General and administrative increase of 49% to $58.5M (expense) Realized gains on investments and other decrease of 92% to $69K (income). |
ARRYのテクニカル分析
ARRYのニュース
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings 2019/07/30 11:00:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted …
Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit (MYL, PFE) 2019/07/29 12:37:00 Business Insider
Shares of Mylan surged more than 20% in early trading on Monday after the EpiPen maker agreed to merge with Pfizer's off-patent drug unit. Pfizer shareholders will own 57% of the new company, and the remainder will be owned by shareholders of Mylan, according to a statement from the companies. The new drugmaker will be rebranded and renamed, and is expected to generate between $19 billion and $20 billion in annual sales. Watch Mylan trade live . Mylan , the drugmaker behind the life-saving EpiPen, has agreed to merge with Pfizer's off-patent drug unit in a deal that will create a new pharmaceutical company with as much as $20 billion in annual sales. News of the deal sent shares of Mylan soaring more than 20% in early trading on Monday. Meanwhile, Pfizer slid by about 2%. Pfizer's off-patent drug business operates under the brand Upjohn, and sells well-known medicines such as Lipitor and Viagra. Pfizer shareholders will own 57% of the new company, and shareholders of Mylan will own he remaining 43%.
Array BioPharma (ARRY) Moves to Buy: Rationale Behind the Upgrade 2019/07/25 13:00:08 Zacks Investment Research
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer Is Looking Pretty Smart With Array BioPharma Purchase 2019/07/08 13:34:00 Barron's
New results from a colorectal cancer study by Array BioPharma seem to validate Pfizer’s decision last month to acquire the drug company for $10.6 billion.
4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan 2019/06/26 18:45:00 Business Insider
AbbVie's recent deal for the pharmaceutical company Allergan is the latest in a string of healthcare M&A this year that has shifted the pharmaceutical industry's landscape. AbbVie is betting on Allergan's cosmetic products, like Botox, and other medical areas like women's health, neuroscience, eye care, and more. Analysts at Stifel say four biotechs could also be the next takeover targets: Revance Therapeutics, TherapeuticsMD, Aerie Pharmaceuticals, and Kala Pharmaceuticals. Click here for more BI Prime stories. US drugmaker AbbVie just announced a mega-deal to buy pharmaceutical company Allergan for about $63 billion. It's only the latest in a string of active healthcare deals this year , with Bristol-Myers Squibb's $74 billion proposed acquisition of Celgene and Eli Lilly's $8 billion agreement to buy the biotech Loxo Oncology in January. With Tuesday's deal, AbbVie is betting on Allergan cosmetic products like the well-known filler Botox and fat-freezing procedure CoolSculpting. But the drugmaker also clearly values Allergan's other medical treatments in areas like women's health, neuroscience, eye care and more, noted Stifel analysts Annabel Samimy and Nick Runibo. "This demonstration of interest could bring a host of other transactions that complement and build on franchises that [AbbVie] appears more committed to than [Allergan] has been," they said.
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings 2019/07/30 11:00:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted …
Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit (MYL, PFE) 2019/07/29 12:37:00 Business Insider
Shares of Mylan surged more than 20% in early trading on Monday after the EpiPen maker agreed to merge with Pfizer's off-patent drug unit. Pfizer shareholders will own 57% of the new company, and the remainder will be owned by shareholders of Mylan, according to a statement from the companies. The new drugmaker will be rebranded and renamed, and is expected to generate between $19 billion and $20 billion in annual sales. Watch Mylan trade live . Mylan , the drugmaker behind the life-saving EpiPen, has agreed to merge with Pfizer's off-patent drug unit in a deal that will create a new pharmaceutical company with as much as $20 billion in annual sales. News of the deal sent shares of Mylan soaring more than 20% in early trading on Monday. Meanwhile, Pfizer slid by about 2%. Pfizer's off-patent drug business operates under the brand Upjohn, and sells well-known medicines such as Lipitor and Viagra. Pfizer shareholders will own 57% of the new company, and shareholders of Mylan will own he remaining 43%.
Array BioPharma (ARRY) Moves to Buy: Rationale Behind the Upgrade 2019/07/25 13:00:08 Zacks Investment Research
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer Is Looking Pretty Smart With Array BioPharma Purchase 2019/07/08 13:34:00 Barron's
New results from a colorectal cancer study by Array BioPharma seem to validate Pfizer’s decision last month to acquire the drug company for $10.6 billion.
4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan 2019/06/26 18:45:00 Business Insider
AbbVie's recent deal for the pharmaceutical company Allergan is the latest in a string of healthcare M&A this year that has shifted the pharmaceutical industry's landscape. AbbVie is betting on Allergan's cosmetic products, like Botox, and other medical areas like women's health, neuroscience, eye care, and more. Analysts at Stifel say four biotechs could also be the next takeover targets: Revance Therapeutics, TherapeuticsMD, Aerie Pharmaceuticals, and Kala Pharmaceuticals. Click here for more BI Prime stories. US drugmaker AbbVie just announced a mega-deal to buy pharmaceutical company Allergan for about $63 billion. It's only the latest in a string of active healthcare deals this year , with Bristol-Myers Squibb's $74 billion proposed acquisition of Celgene and Eli Lilly's $8 billion agreement to buy the biotech Loxo Oncology in January. With Tuesday's deal, AbbVie is betting on Allergan cosmetic products like the well-known filler Botox and fat-freezing procedure CoolSculpting. But the drugmaker also clearly values Allergan's other medical treatments in areas like women's health, neuroscience, eye care and more, noted Stifel analysts Annabel Samimy and Nick Runibo. "This demonstration of interest could bring a host of other transactions that complement and build on franchises that [AbbVie] appears more committed to than [Allergan] has been," they said.
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings 2019/07/30 11:00:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted …
Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit (MYL, PFE) 2019/07/29 12:37:00 Business Insider
Shares of Mylan surged more than 20% in early trading on Monday after the EpiPen maker agreed to merge with Pfizer's off-patent drug unit. Pfizer shareholders will own 57% of the new company, and the remainder will be owned by shareholders of Mylan, according to a statement from the companies. The new drugmaker will be rebranded and renamed, and is expected to generate between $19 billion and $20 billion in annual sales. Watch Mylan trade live . Mylan , the drugmaker behind the life-saving EpiPen, has agreed to merge with Pfizer's off-patent drug unit in a deal that will create a new pharmaceutical company with as much as $20 billion in annual sales. News of the deal sent shares of Mylan soaring more than 20% in early trading on Monday. Meanwhile, Pfizer slid by about 2%. Pfizer's off-patent drug business operates under the brand Upjohn, and sells well-known medicines such as Lipitor and Viagra. Pfizer shareholders will own 57% of the new company, and shareholders of Mylan will own he remaining 43%.
Array BioPharma (ARRY) Moves to Buy: Rationale Behind the Upgrade 2019/07/25 13:00:08 Zacks Investment Research
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer Is Looking Pretty Smart With Array BioPharma Purchase 2019/07/08 13:34:00 Barron's
New results from a colorectal cancer study by Array BioPharma seem to validate Pfizer’s decision last month to acquire the drug company for $10.6 billion.
4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan 2019/06/26 18:45:00 Business Insider
AbbVie's recent deal for the pharmaceutical company Allergan is the latest in a string of healthcare M&A this year that has shifted the pharmaceutical industry's landscape. AbbVie is betting on Allergan's cosmetic products, like Botox, and other medical areas like women's health, neuroscience, eye care, and more. Analysts at Stifel say four biotechs could also be the next takeover targets: Revance Therapeutics, TherapeuticsMD, Aerie Pharmaceuticals, and Kala Pharmaceuticals. Click here for more BI Prime stories. US drugmaker AbbVie just announced a mega-deal to buy pharmaceutical company Allergan for about $63 billion. It's only the latest in a string of active healthcare deals this year , with Bristol-Myers Squibb's $74 billion proposed acquisition of Celgene and Eli Lilly's $8 billion agreement to buy the biotech Loxo Oncology in January. With Tuesday's deal, AbbVie is betting on Allergan cosmetic products like the well-known filler Botox and fat-freezing procedure CoolSculpting. But the drugmaker also clearly values Allergan's other medical treatments in areas like women's health, neuroscience, eye care and more, noted Stifel analysts Annabel Samimy and Nick Runibo. "This demonstration of interest could bring a host of other transactions that complement and build on franchises that [AbbVie] appears more committed to than [Allergan] has been," they said.